Relapse after autologous hematopoietic stem cell transplantation (ASCT) is still challenging for high-risk aggressive lymphoma. This study was to investigate the efficacy and safety of maintenance therapy post-ASCT.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
60
Rituximab vs DPP/DCEP-G vs observation
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
RECRUITINGRelapse rate
Time frame: 2 years
Overall survival
Time frame: 2 years
Treatment-related mortality
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.